Cargando…
Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia. Amyloid-β (Aβ(42)) is implicated in AD pathogenesis. We have designed a non-immune based proprietary therapeutic, called Amytrap, a conjugate containing a retro-inverso peptide, polyethylene glycol, and human serum albumin. Amytrap not o...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IOS Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597960/ https://www.ncbi.nlm.nih.gov/pubmed/31259305 http://dx.doi.org/10.3233/ADR-190107 |